Carvykti (ciltacabtagene autoleucel)

Numéro de dossier de l’APP: 22363
État des négociations:
En négociation
Indication(s):
For the treatment of adult patients with multiple myeloma (MM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and who are refractory to their last treatment.
Promoteur/fabricant:
Janssen Inc.
Numéro de projet de l’ACMTS:
PG0302
Lettre-contrat de l’APP:
Conclusion du processus de négociation:
Sans objet